Some
microRNAs are usually dysregulated in the
cancers and influencing
tumor behavior and progression.
Hsa-miR-181b-1 and its target CYLD are involved in regulating the inflammatory pathways. This study aimed to investigate the expression levels of
hsa-mir-181b-1 and CYLD in a cohort of
breast tumor tissues and normal adjacent tissues to assess their association with
breast cancer stages. A total number of 60 breast samples including cancerous and normal adjacent tissue specimens were collected. After pathological study, the expression of
hsa-mir-181b-1 and CYLD were measured by qRT-PCR method. The
hsa-mir-181b-1 expression level was significantly increased in
breast tumor tissues compared to the controls. This increase was associated with the
disease progression. Conversely, CYLD expression level was decreased in
tumor samples compared to normal samples, significantly. ROC curve data added other prestigious information of
hsa-mir-181b-1 and CYLD by defining
cancer and healthy tissues with high specificity and sensitivity at a proposed cutoff point. Also, bioinformatic enrichment for the possible targets of mature sequence of "hsa-mir-181b-5p" was performed. Computational analysis showed the five most significant pathways including metabolic,
cancer, calcium signaling, PI3K-Akt signaling and focal adhesion pathways which may be influenced by
hsa-mir-181b-1. Thus, we suggested
hsa-mir-181b-1 and CYLD might be involved in the pathogenesis of
breast cancer and could be considered as two
biomarkers for prediction, prognosis and diagnosis of the stages of the
breast cancer.